by Vincent Van der Wel | Feb 11, 2025 | Blog
Over the past decades its popularity has increased, especially amongst academics. In 2010, there were only 57 publications on drug repurposing. By 2024, this number has increased to over 2300 publications, reflecting the increased interest and activity in the field of...
by Barbara Van den Aarsen | Jan 9, 2025 | Blog
The main challenges encountered during clinical trials include patient recruitment and retention, but also regulatory hurdles and methodological complexities need to be overcome. Drug repurposing is one of the possibilities used by Orfenix that aims to ease the...
by Hellen Houlleberghs | Nov 21, 2024 | Blog
Understanding EMA scientific advice The European Medicines Agency (EMA) scientific advice procedure was introduced with the aim to improve communication between companies developing medicinal products (sponsors) and regulators to enable streamlining of the development...
by Ivo De Nooijer | Nov 12, 2024 | Blog
Drug development is a long, expensive, and risky process. It takes an average of 10-15 years and requires a multi billion investment to bring a new drug from the laboratory to patients. Despite these costs, only about 10% of drugs that begin clinical trials ever...
by Ivo De Nooijer | Oct 17, 2024 | Blog
Orfenix welcomes a recently published report of the Medicines Patent Pool, in partnership with Boston Consulting Group, shows how voluntary licensing brings both improved access to medicines, in particular in low and middle-income countries and economic benefits to...
by Ivo De Nooijer | Oct 17, 2024 | Blog
Orfenix is proud to announce that Ivo de Nooijer has formally joined Orfenix as a shareholder and partner as of 1 July 2024. Vincent van de Wel, the founder, said, “Ivo joining this team is the next step in the development of Orfenix; Ivo brings extensive expertise in...
